Bridgepoint

CG Results Healthcare advises Bridgepoint on its acquisition of PharmaZell

CG Results Healthcare is pleased to announce that it has provided transaction advisory support to Bridgepoint on its acquisition of PharmaZell.

PharmaZell, a leading independent manufacturer of niche active pharmaceutical ingredients (APIs), was acquired by Bridgepoint from DPE Deutsche Private Equity and Maxburg Capital Partners for an undisclosed sum. CG Results Healthcare was selected to support on this transaction due to its specialist team and exceptional track record in the pharmaceutical manufacturing sector.

PharmaZell is a market leader in the highly resilient and specialty API market where it has a diversified portfolio of over 70 APIs, and enjoys leading industry positions in several products that treat respiratory, inflammatory and liver diseases driven by changing lifestyle habits. Many of the Company’s products require special handling procedures and/or technologies. Headquartered in Raubling (near Munich), PharmaZell operates four state-of-the-art production and R&D sites in Germany, Italy and India with over 900 employees globally.

The global market for small molecule APIs is estimated at over $70bn and growing continuously, driven by rising health standards and increasing drug consumption in emerging markets. In addition, the trend to outsourcing continues driven by cost optimisation and streamlining initiatives by the pharma majors.

This is CG Results Healthcare’s second transaction in the API manufacturing space in the last 12 months, after the acquisition of Sterling Pharma by GHO.